Structural investigation of a bispecific antibody for treatment of HER2-expressing cancers

Zanidatamab is an antibody being evaluated in clinical trials to treat breast cancer, biliary tract cancer and gastroesophageal adenocarcinomas linked to the overabundance of a protein known as HER2. Zanidatamab was developed to bind to two copies of HER2 in tandem instead of one, increasing its binding affinity and improving its inhibition of HER2 tumor-promoting activities. The binding of each zanidatamab to two copies of HER2 is proposed to form a network of HER2 linked by zanidatamab.

Computational design for improving the affinity of peptide ligands for carbohydrate-binding

Diarrhoeal diseases pose a serious global problem, especially in the developing world. Shigella flexneri Y, the most deadly species of Shigella, is endemic in most developing countries. An antibody, SYA/J6, against Shigella flexneri Y was developed. Studies have shown that MDWNMHAA is a weakly immunogenic peptide against the antibody SYA/J6. The research team at Zymeoworks Inc., a computational biotechnology company, is hoping to improve the binding of MDWNMHAA to SYA/J6 in order to generate a more effective immune response. This could lead to a vaccine for Shigella flexneri Y.

Computational/Experimental Protocol for Development of a Therapeutic Agent for Treatment of Tuberculosis

It is estimated that one third of the world’s population is infected by Mycobacterium tuberculosis. With the emergence of drug resistant tuberculosis, the World Health Organization has declared tuberculosis a global health emergency. UDP-galactopyranose mutase, an enzyme essential for tuberculosis bacterial growth and infection, will be studied by a protocol which combines advanced NMR and computational modeling techniques.

Antibody Modeling Using a Combined Computational/Experimental Protocol

The proposed project combines structural biochemistry with high-performance molecular simulations to generate valuable insight into the development of the next generation of ligands that can be used to develop vaccines. The collaboration between the academic and industry partner creates an ideal opportunity to combine theoretical and experimental approaches for better lead generation and development of scientific knowledge. Zymeworks will have an opportunity to validate its ZymeCAD™ platform for pharmaceutical applications.